Evaluation of Patients With Breast Cancer Using Dynamic Contrast-Enhanced Magnetic Resonance Imaging, Magnetic Resonance Spectroscopy, and Proteomics
- To correlate data obtained by DCE-MRI and MRS in healthy women and in women who are
undergoing surgery for breast cancer with data obtained by conventional X-ray
mammography, tissue proteomics, and histopathology.
- To evaluate the impact of MRSI data on treatment planning for radiotherapy and/or
OUTLINE: Healthy participants undergo dynamic contrast-enhanced (DCE)-MRI and magnetic
resonance spectroscopic (MRS) for longitudinal studies of breast imaging and spectroscopy.
Patients with breast cancers undergo DCE-MRI and MRS prior to initiation of treatment (i.e.,
surgery, chemotherapy, or radiotherapy). After treatment has begun, patients then undergo
repeat imaging (not more than 1 per month) for follow-up assessments and longitudinal
Breast tissue samples are collected from patients undergoing surgery. Samples are evaluated
by histopathological and proteomic analysis for correlation with DCE-MRI and MRS findings.
The study interventions are discontinued after definitive surgery is performed.
PROJECTED ACCRUAL: A total of 10 healthy participants and 40 patients with breast cancer
will be accrued for this study.
Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic
Correlation of data obtained by DCE-MRI and magnetic resonance spectroscopy (MRS) with data obtained by conventional X-ray mammography, tissue proteomics, and histopathology in women with breast cancer
Imaging and spectroscopic studies are performed before surgery. After surgery, this data will be compared and contrast with data obtained from conventional mammograms and the patient's tissue.
At time of breast surgery
A. Bapsi Chakravarthy, MD
Vanderbilt-Ingram Cancer Center
United States: Federal Government
VICC BRE 0358